ER PROTAC degrader · degrader

vepdegestrant

0 active trials, targeting ER. 1 active approval for a biomarker on marked.bio.

Also known as ARV-471.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Approvals and pivotal results

Biomarker-selected approvals in the United States and the European Union, with the pivotal trial's results and side effects where we have them. Results from different trials are not directly comparable.

Therapy	Biomarker	Tumour	United States	European Union
vepdegestrant FDA, 2026 advanced or metastatic, ESR1-mutated, after >=1 line of endocrine therapy FDA approval 01/05/2026; companion test Guardant360 CDx. Source Veppanu	ESR1 mutation	breast (ER+/HER2-)	Approved 2026	Not approved
VERITAC-2 vs fulvestrant, 270 with ESR1 mutation PFS 5.0 months vs 2.1 months, HR 0.57 (0.42-0.77)Response 19% vs 4% Serious side effects 9%Stopped for side effects 2.9%Fatal 1.0% Trial details and side effects Patients ESR1-mutated ER+/HER2- advanced breast cancer after CDK4/6 inhibitor (NCT05654623) Most common side effects musculoskeletal pain 30%, fatigue 29%, nausea 14%, decreased appetite 11%, constipation 10%, QT prolongation 10% (312 patients) Notes FDA approval summary (2026); OS immature. Warnings: QTc prolongation. Side effects: Veppanu US label, section 6 (VERITAC-2), via RxList. Source FDA approval summary

Biomarkers

Biomarker	Active trials	All trials	Furthest active phase

Trials

0 of 0 trials shown